Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

Nanoscope has received a new patent ( US Patent No. 12459977) from the US Patent and Trademark Office (USPTO) for the company ...

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening diseaseNORWICH, England & ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

We’ve turned the calendar on 2026, and the market’s focus is on what comes next. The big questions haven’t changed: can the ...

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

Novel capsid technology to enable convenient delivery in the doctor's office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease Ikarovec Ltd, which is devel ...

Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...

Ophthalmologists recognized at the ‘Surgical Strike 360’ conference in Chennai, showcasing innovative techniques and ...

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...

Ohm J . Über die Behandlung der Netzhautablosung durch operative Entleerung der subretinalen Flussigkeit und Einspritzung von Luft in den Glaskörper. Graefes Arch Klin Exp Ophthalmol 1911;79:442–50.